title: Two Relapsed Stage III Childhood Anaplastic Large Cell Lymphoma Patients with NPM-ALK Fusion in Bone Marrow from Initial Diagnosis.
abstract: Childhood anaplastic large cell lymphoma (ALCL) accounts for approx. 10-30% of cases of non-Hodgkin lymphoma, and the ALCL99 study reported 60-75 disease-free survival; however, a relatively high relapse rate was observed (25-30% ). We report 2 patients with Stage III ALCL who relapsed 6-18 months after the end of ALCL99 chemotherapy. A retrospective molecular analysis identified the nucleophosmin (NPM)-anaplastic lymphoma kinase (ALK) fusion gene in the first diagnostic bone marrow samples taken from both patients. However, antibodies against the ALK protein appeared to be relatively low in the serum of both patients (×100 and ×750). An increase in chemotherapy intensity may be beneficial if Stage III ALCL patients are shown to be NPM-ALK chimera-positive in the first diagnostic bone marrow sample.
authors.affiliation: Department of Pediatrics, Okayama University Hospital, Okayama 700-8558, Japan.
authors.forename: Yui
authors.initials: Y
authors.lastname: Kanazawa
authors.forename: Yuka
authors.initials: Y
authors.lastname: Yamashita
authors.forename: Mitsuhiro
authors.initials: M
authors.lastname: Fujiwara
authors.forename: Michiko
authors.initials: M
authors.lastname: Muraoka
authors.forename: Kana
authors.initials: K
authors.lastname: Washio
authors.forename: Kiichiro
authors.initials: K
authors.lastname: Kanamitsu
authors.forename: Hisashi
authors.initials: H
authors.lastname: Ishida
authors.forename: Takae
authors.initials: T
authors.lastname: Nakano
authors.forename: Miho
authors.initials: M
authors.lastname: Yamada
authors.forename: Keizo
authors.initials: K
authors.lastname: Horibe
authors.forename: Takehiro
authors.initials: T
authors.lastname: Tanaka
authors.forename: Tadashi
authors.initials: T
authors.lastname: Yoshino
authors.forename: Akira
authors.initials: A
authors.lastname: Shimada
mesh_terms: D000077548:Anaplastic Lymphoma Kinase; D000912:Antibodies, Neoplasm / Q000097:blood; D000970:Antineoplastic Agents / Q000627:therapeutic use; D002648:Child; D006801:Humans; D017728:Lymphoma, Large-Cell, Anaplastic / Q000188:drug therapy / Q000473:pathology*; D020794:Receptor Protein-Tyrosine Kinases / Q000276:immunology; D012008:Recurrence
chemical_list: D000912:Antibodies, Neoplasm; D000970:Antineoplastic Agents; C000626173:ALK protein, human; D000077548:Anaplastic Lymphoma Kinase; D020794:Receptor Protein-Tyrosine Kinases